Cara CDRS (Conduction Disturbance Risk Score) 1.0

Active, not recruiting

• Conditions: Transcatheter Aortic Valve Replacement
• Interventions: Device: ECG monitoring

• Registration Number: NCT05657912
• Lead Sponsor: Cara Medical Ltd

Brief Summary

Prospective, non-randomized, multicenter data collection study. Eligible TAVR patients will be enrolled in the study.

Cardiac conduction disturbances (CD) requiring permanent pacemaker implantation (PPM) or causing new-onset CD are frequent complications of TAVR that have been shown to be associated with increased mortality and re-hospitalization rates.

The purpose of the study is to collect continuous ECG data in order to validate the performance of the Cara Conduction Disturbance Risk Score (CDRS) in patients undergoing transcatheter aortic valve replacement (TAVR).

Subjects will be studied during the TAVR procedure and their ECG recordings according to the study schedule below of pre-, during, and after the TAVR procedure up to 14/30 days FU will be collected.

600 patients will be enrolled in this study with the hypothesis that Cara can deliver a statistically significant conduction disturbance risk stratification for patients undergoing TAVR.

No investigation intervention is planned during this study. The Cara System analysis will be performed offline.

Detailed Description

TAVR will be performed using site investigators' best practices including the use of standard-of-care catheters, devices, imaging, and monitoring modalities.

Data will be collected to include the following patients' measures during this study:

1. Pre-procedure

1. Demographics

2. Medical history

3. Cardiac CT

4. 12 lead ECG

2. Procedure

1. Continuous 3-12 lead Holter will be supplied, data will be collected and analyzed by the study sponsor

2. Fluoroscopy (captured automatically by video system )

3. Device manufacturer (type) and size

3. Post-procedure (in hospital)

a. Continuous 1-3 lead Holter for 14 days will be supplied, and the data from the Holter recordings will be collected from the patient's home and analyzed.

4. Post-procedure (discharge)

a. 12 lead ECG

5. Patients will be followed according to the current medical practice.

Data to be collected during the FU :

a. 12 lead ECG at 14/30 days

The data collected from the study will be used to evaluate the performance Cara System, a conduction disturbance monitor that provides an indication of conduction disturbances during TAVR procedures.

Conduction Disturbances (CD) outcome will be subdivided into:

1. PPM or High-Grade AV Block (HGAVB)

2. All other new onsets (or deterioration) of CD that are not listed in #1

3. No new onset CD

Study Timeline

• Study Start: 2022-12-12
• Study First Submitted: 2022-12-12
• Study First Submitted QC: 2022-12-19
• Study First Posted: 2022-12-20
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-12
• Last Update Posted: 2025-02-13
• Primary Completion: 2025-05-31
• Study Completion: 2025-05-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Must meet be ≥ 18 years of age.
• Must meet indications for TAVR using approved devices
• Provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
• Willing to comply with specified follow-up evaluations.
• Must meet the legal minimum age to provide Informed Consent based on local regulatory requirements.

Exclusion Criteria

• Any implanted device or an indication for treatment with a rhythm management device (i.e., pacemaker, Cardiac Resynchronization Therapy (CRT), or Cardiac Resynchronization Therapy with cardioverter-defibrillator (CRT-D) at baseline.
• Any contraindication to the TAVR procedure according to the instructions for use.
• Less than the legal age of consent, legally incompetent, or otherwise vulnerable.
• Planned treatment with any other investigational device, drug, or procedure (excluding registries) during the study period.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
ECG Monitoring -TAVR patients	ECG monitoring	Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure

Primary Outcome Measures

Name	Time	Method
Estimated reduction of New Onset Conduction Disturbances NOCD (percentage) at 14 days post TAVR while using Cara Monitor	14 days	Continuous ECG data collected during the TAVR procedure will be used to retrospectively evaluate the performance of the Cara monitor Conduction Disturbance Risk Score (CDRS) in patients post- TAVR procedure.; Measured output: 1. Patients who receive PaceMaker (PPM) 14 days following TAVr (PPM+); 2. Patients that do not receive PaceMaker (PPM) 14 days following TAVr (PPM-)

Trial Locations

Locations (3)

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval; 🇨🇦 Québec, Canada

Policlinico San Donato; 🇮🇹 Milano, Italy

Hospital Clínic de Barcelona; 🇪🇸 Barcelona, Spain